[go: up one dir, main page]

MC1883A1 - Derives de tetrahydronaphtalene - Google Patents

Derives de tetrahydronaphtalene

Info

Publication number
MC1883A1
MC1883A1 MC871928A MC1928A MC1883A1 MC 1883 A1 MC1883 A1 MC 1883A1 MC 871928 A MC871928 A MC 871928A MC 1928 A MC1928 A MC 1928A MC 1883 A1 MC1883 A1 MC 1883A1
Authority
MC
Monaco
Prior art keywords
isopropyl
ethyl
tetrahydro
methyl
methylamino
Prior art date
Application number
MC871928A
Other languages
English (en)
French (fr)
Inventor
Branca Quirico
Jaunin Roland
Peter Marki Hans
Marti Fraenzi
Ramuz Henri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MC1883A1 publication Critical patent/MC1883A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/64Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Luminescent Compositions (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Insulating Materials (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
MC871928A 1986-11-14 1987-11-12 Derives de tetrahydronaphtalene MC1883A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH456586 1986-11-14

Publications (1)

Publication Number Publication Date
MC1883A1 true MC1883A1 (fr) 1989-01-24

Family

ID=4278454

Family Applications (1)

Application Number Title Priority Date Filing Date
MC871928A MC1883A1 (fr) 1986-11-14 1987-11-12 Derives de tetrahydronaphtalene

Country Status (31)

Country Link
US (1) US4808605A (sv)
EP (1) EP0268148B1 (sv)
JP (1) JP2504490B2 (sv)
KR (1) KR960004863B1 (sv)
CN (1) CN1028991C (sv)
AT (1) ATE70267T1 (sv)
AU (1) AU600769B2 (sv)
BG (1) BG60937B2 (sv)
CA (1) CA1319144C (sv)
CS (2) CS264350B2 (sv)
DE (2) DE19775076I2 (sv)
DK (1) DK171349B1 (sv)
DZ (1) DZ1142A1 (sv)
ES (1) ES2040234T3 (sv)
FI (1) FI94414C (sv)
GR (1) GR3004029T3 (sv)
HK (1) HK110494A (sv)
HU (1) HU215915B (sv)
IE (1) IE60695B1 (sv)
IL (1) IL84407A (sv)
LV (1) LV5745B4 (sv)
MC (1) MC1883A1 (sv)
MX (1) MX173614B (sv)
NL (1) NL970019I2 (sv)
NO (2) NO172237C (sv)
NZ (1) NZ222474A (sv)
PH (1) PH23919A (sv)
PT (1) PT86130B (sv)
SG (1) SG114194G (sv)
ZA (1) ZA878362B (sv)
ZW (1) ZW20087A1 (sv)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003283A1 (en) * 1988-12-05 1990-06-05 C. Anne Higley Imidazoles for the treatment of atherosclerosis
CA2011461A1 (en) * 1989-03-20 1990-09-20 Urs Hengartner Tetrahydronaphthalene derivatives
NL9001522A (nl) * 1990-07-04 1992-02-03 Schreiner Luchtvaart Werkwijze voor het vervaardigen van een voorwerp bestaande uit een schuimkern en eventueel een of meer afdeklagen.
TW216770B (sv) * 1991-07-23 1993-12-01 Hoffmann La Roche
US5663166A (en) * 1991-10-18 1997-09-02 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
BR9509760A (pt) * 1994-11-23 1998-06-30 Neurogen Corp Composto
ATE215108T1 (de) 1995-06-23 2002-04-15 Univ Delft Tech Verfahren zur herstellung eines schäumbaren filmes
US5910606A (en) * 1996-01-31 1999-06-08 Hoffmann-La Roche Inc. Process for making α,β-unsaturated carboxylic acids
US5811556A (en) * 1997-04-30 1998-09-22 Roche Colorado Corporation Preparation of mibefradil via a naphthalenylacetic acid
US5811557A (en) * 1997-04-30 1998-09-22 Roche Colorado Corporation Preparation of mibefradil via an acetonitrile anion
US5808088A (en) * 1997-04-30 1998-09-15 Roche Colorado Corporation Preparation of mibefradil via an acetamide anion
US6897305B2 (en) * 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US7101909B2 (en) * 1998-10-12 2006-09-05 Theravance, Inc. Calcium channel drugs and uses
AR030676A1 (es) * 1999-07-28 2003-09-03 Ortho Mcneil Pharm Inc Derivados de aminas y amidas como ligandos para el receptor del neuropeptido y y5 utiles en el tratamiento de la obesidad y otros trastornos, uso de los mismos para la elaboracion de medicamentos y composiciones farmaceuticas que los comprenden
WO2001062741A1 (en) * 2000-02-25 2001-08-30 South Alabama Medical Science Foundation Tetrahydronaphtalene derivatives and their use
AU2001235363A1 (en) * 2000-02-25 2001-09-03 Novo-Nordisk A/S Mibefradil analogues and their use
ES2274854T3 (es) * 2000-05-08 2007-06-01 Pfizer Products Inc. Resolucion enzimatica de moduladores selectivos del receptor de estrogeno.
FR2827862A1 (fr) * 2001-07-27 2003-01-31 Lipha Derives imidazolylalkylarylalcanoiques et leurs applications en therapeutique
WO2003031415A1 (en) * 2001-10-10 2003-04-17 Aryx Therapeutics Mibefradil-based compounds as calcium channel blockers useful in the treatment of hypertension and angina
KR20030037081A (ko) * 2001-11-02 2003-05-12 한국과학기술연구원 T 타입 칼슘채널을 조절하여 복통을 억제하는 방법
AU2003250483A1 (en) 2002-08-19 2004-03-11 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
ES2313079T3 (es) * 2003-07-28 2009-03-01 Janssen Pharmaceutica Nv Benzimidazol, benzotiazol, benzoxazol y su utilizacion como moduladores de lta4h.
WO2006014930A2 (en) * 2004-07-26 2006-02-09 Cotherix, Inc. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
EP2111863B1 (en) 2005-10-26 2012-03-28 Asahi Kasei Pharma Corporation Fasudil in combination with bosentan for the treament of pulmonary arterial hypertension
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
BRPI0810399B8 (pt) * 2007-04-27 2021-05-25 Actelion Pharmaceuticals Ltd composto, composição farmacêutica que o contém e uso do mesmo
PT2336125E (pt) * 2008-04-11 2013-03-18 Janssen Pharmaceutica Nv Tiazolopiridina-2-iloxi-fenil e tiazolopirazin-2-iloxifenil aminas como moduladores de leucotrieno a4 hidrolase
US20110039905A1 (en) 2008-04-25 2011-02-17 Francis Hubler Benzimidazole derivatives as calcium channel blockers
JP2012506415A (ja) 2008-10-22 2012-03-15 アクテリオン ファーマシューティカルズ リミテッド 架橋テトラヒドロナフタレン誘導体
WO2010046729A2 (en) * 2008-10-23 2010-04-29 Actelion Pharmaceuticals Ltd Tetrahydronaphthalene compounds
EP2451944A4 (en) 2009-07-10 2012-11-28 Harvard College PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS
US8513434B2 (en) 2010-03-02 2013-08-20 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US8883844B2 (en) 2010-09-24 2014-11-11 Nitrogenix Inc. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
DK3364993T3 (da) 2015-10-22 2023-01-09 Cavion Inc Fremgangsmåder til behandling af angelman syndrom
CN110545806A (zh) * 2017-02-15 2019-12-06 卡维昂公司 钙通道抑制剂
MX2019012818A (es) 2017-04-26 2020-07-14 Cavion Inc Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
CA3115235A1 (en) 2018-10-03 2020-04-09 Cavion, Inc. Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
FI3911648T3 (fi) 2019-01-18 2025-01-10 Astrazeneca Ab 6'-[[[(1s,3s)-3-[[5-(difluorometoksi)-2-pyrimidinyyli]amino]syklopentyyli]amino][1(2h),3'-bipyridin]-2-oni pcsk9:n estäjänä ja menetelmät sen käyttöön
CN115850119A (zh) * 2022-11-26 2023-03-28 南昌大学 一种2-氯芳香胺类化合物的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914216A (en) * 1962-12-18 1975-10-21 Boehringer Sohn Ingelheim 1-Phenyl-3H-1,4-benzodiazepine-2,5-(1H,4H)-diones
BE793460A (fr) * 1971-12-29 1973-06-28 Boehringer Sohn Ingelheim Nouvelles 1-aryl-3h,1,4-benzodiazepine-2,5-(1h
NZ213651A (en) * 1984-10-11 1989-07-27 Hoffmann La Roche Tetrahydronapthalene derivatives and medicaments

Also Published As

Publication number Publication date
KR960004863B1 (en) 1996-04-16
CS264350B2 (en) 1989-07-12
GR3004029T3 (sv) 1993-03-31
NO1998001I1 (no) 1998-01-09
KR880006163A (ko) 1988-07-21
SG114194G (en) 1994-11-25
NZ222474A (en) 1990-02-26
DK171349B1 (da) 1996-09-16
CS787487A2 (en) 1988-11-15
IL84407A0 (en) 1988-04-29
US4808605A (en) 1989-02-28
MX9271A (es) 1993-09-01
JP2504490B2 (ja) 1996-06-05
FI94414B (sv) 1995-05-31
CN1028991C (zh) 1995-06-21
CN87107875A (zh) 1988-05-25
PT86130B (pt) 1990-11-20
IE873070L (en) 1988-05-14
LV5745A4 (lv) 1996-10-20
PH23919A (en) 1990-01-23
FI875024A0 (sv) 1987-11-13
AU8090987A (en) 1988-05-19
ZA878362B (en) 1988-05-16
NL970019I1 (nl) 1997-08-01
ES2040234T3 (es) 1993-10-16
IL84407A (en) 1991-09-16
NO172237C (no) 1993-06-23
ZW20087A1 (en) 1988-07-20
HU215915B (hu) 1999-03-29
DK559987D0 (da) 1987-10-26
AU600769B2 (en) 1990-08-23
EP0268148B1 (de) 1991-12-11
HK110494A (en) 1994-10-21
IE60695B1 (en) 1994-08-10
NO172237B (no) 1993-03-15
DE3775177D1 (de) 1992-01-23
NO874757L (no) 1988-05-16
JPS63139171A (ja) 1988-06-10
HUT60251A (en) 1992-08-28
LV5745B4 (lv) 1996-12-20
ATE70267T1 (de) 1991-12-15
DE19775076I2 (de) 2001-08-09
BG60937B2 (bg) 1996-06-28
CS394891A3 (en) 1992-06-17
NO874757D0 (no) 1987-11-13
DZ1142A1 (fr) 2004-09-13
FI875024A7 (sv) 1988-05-15
FI94414C (sv) 1995-09-11
CA1319144C (en) 1993-06-15
PT86130A (en) 1987-12-01
DK559987A (da) 1988-05-15
MX173614B (es) 1994-03-18
EP0268148A1 (de) 1988-05-25
NL970019I2 (nl) 1997-11-03

Similar Documents

Publication Publication Date Title
MC1883A1 (fr) Derives de tetrahydronaphtalene
EP0497659B1 (fr) Dérivés d'aryl (ou hétéroaryl)-piperaz inyl-alkyl-azoles, leur préparation et leur application en tant que médicaments
EP0202164B1 (fr) Dérivés de (benzoyl-4 pipéridino)-2 phenyl-1 alcanols, leur préparation et leur application en thérapeutique
FR2488890A1 (fr) Derives tricycliques de l'imidazole, leur preparation et leurs utilisations therapeutiques
EP0162036A1 (fr) (S)-alpha-éthyl-2-oxo-1-pyrrolidineacétamide
EP0507696B1 (fr) Antihistaminiques non sédatifs, dérivés de benzimidazole, leur procédé de préparation et leur utilisation en tant que médicaments.
EP0307303B1 (fr) [(Pyrimidinyl-2)-aminoalkyl]-1 pipéridines, leur préparation et leur application en thérapeutique
MC1210A1 (fr) Nouveaux nitroimidazoles et procede pour leur preparation
LU81985A1 (fr) Nouveaux derives d'imidazole,leur procede de production et composition pharmaceutique les contenant
LU82087A1 (fr) N-benzylimidazoles inhibiteurs selectifs de thromboxannesynthetase,leur procede de production et compositions pharmaceutiques les contenant
EP0468884B1 (fr) Nouveaux dérivés de benzimidazole, leur préparation, et leur application en tant que médicaments
FR2662696A2 (fr) Antagonistes de la serotonine, leur preparation et medicaments les contenant.
EP0341231B1 (fr) 1-(1H-imidazol-4-yl)alkyl-benzamides substitués
MC1706A1 (fr) Dérivés de tétrahydronaphtalène
EP0835254B1 (fr) Derives d'oxazolidinone, leur preparation et leur application en therapeutique
EP0269599A2 (fr) 1H-Imidazoles substitués
EP0021924B1 (fr) Dérivés de l'indole, procédé pour leur préparation, leur application comme médicaments et compositions pharmaceutiques les contenant
EP0385848A1 (fr) Nouveaux dérivés benzoxazolinoniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
EP0710658A1 (fr) Nouvelles 5-(aryloxymethyl)oxazolines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
CH643243A5 (fr) Cis- et trans-3-aryloxy-4-hydroxypyrrolidines et leurs derives, utiles notamment en medecine veterinaire comme antidepresseurs.
EP0718307A2 (fr) Dérivés de 1-oxo-2-(phénylsulfonyl-amino)pentylpipéridine, leur préparation et leur application en thérapeutique
FR2641534A1 (fr) Nouveaux derives de glycine utiles comme medicaments antagonistes du thromboxane a2 et procede pour leur preparation
MC1962A1 (fr) Derives du benzimidazole
WO1991016323A1 (fr) Derives du naphtosultame antagonistes de la serotonine, leur preparation et les medicaments les contenant
FR2765580A1 (fr) Derives de (1h-imidazol-4-yl)piperidine, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
YP Annual fee paid